Acalabrutinib May Be an Alternative to Ibrutinib For Treatment of CLL
Lori Leslie, MD, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real-word clinics.
Lori Leslie, MD, a lymphoma oncologist at John Theurer Cancer Center, Hackensack University Medical Center, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib (Calquence) in real-word clinics.
New agents are entering the treatment landscape for CLL. Acalabrutinib, a BTK inhibitor, is 1 of the newer drugs that has been approved for the treatment of CLL in the frontline and the relapsed/refractory settings. The difference between acalabrutinib and the other BTK inhibitor, ibrutinib (Imbruvica), is the toxicity profile. Some individuals have become intolerant to ibrutinib, and alternative therapies are needed.
Researchers at John Theurer Cancer Center conducted a real-word outcomes study to evaluate patients treated with acalabrutinib due to ibrutinib intolerance. They discovered that the rate of treatment discontinuation among patients given acalabrutinib was low. This finding suggests that acalabrutinib is a well-tolerated alternative for patients who have developed an intolerance to ibrutinib, says Leslie.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
